About: Human respiratory syncytial virus and other viral infections in infants receiving palivizumab

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Human respiratory syncytial virus and other viral infections in infants receiving palivizumab Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Human respiratory syncytial virus and other viral infections in infants receiving palivizumab
Creator	Boivin, Guy De Serres, Gaston Carbonneau, Julie Caouette, Georges Ouakki, Manale »more»
source	Elsevier; Medline; PMC
abstract	BACKGROUND: Palivizumab is a humanized monoclonal antibody that prevents severe human respiratory syncytial virus (HRSV) infections. OBJECTIVES: We determined the etiology of respiratory viral infections in palivizumab recipients, and monitored the clinical outcome and HRSV genotype in HRSV-infected infants. STUDY DESIGN: Nasopharyngeal aspirates (NPAs) were collected from children receiving palivizumab who consulted or were hospitalized for acute respiratory tract infection (ARTI) during the 2004–2005 season. Viral cultures and multiplex RT-PCR for influenza A/B, HRSV and human metapneumovirus were performed. The fusion (F) gene of HRSV amplicons was also sequenced. RESULTS: Among 116 enrolled patients, 51 (44%) had ≥1 episode of ARTI for a total of 93 visits. At least one virus was identified in 33 (36%) of the 93 NPA samples; HRSV accounted for 11 (33%) of confirmed viral etiologies. Compared to subjects who had other viral ARTI, HRSV-positive subjects had less fever (p = 0.01) and tended to have more bronchiolitis (p = 0.07). Ten subjects (11 visits) developed HRSV infection, although only one was hospitalized. HRSV was detected after a median of 5.5 palivizumab doses and a median of 14 days after the last dose. One of the 11 HRSV strains tested had a F mutation located in the palivizumab-binding site. CONCLUSION: HRSV is still a major cause of ARTI in children receiving palivizumab, although the outcome of infected children appears mild.
has issue date	2008-02-27(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2007.11.012
bibo:pmid	18164233
has license	no-cc
sha1sum (hex)	82b54872490f48eb7da195d7934d347f4ba21692
schema:url	https://doi.org/10.1016/j.jcv.2007.11.012
resource representing a document's title	Human respiratory syncytial virus and other viral infections in infants receiving palivizumab
has PubMed Central identifier	PMC7172843
has PubMed identifier	18164233
schema:publication	J Clin Virol
resource representing a document's body	covid:82b54872490f48eb7da195d7934d347f4ba21692#body_text
is schema:about of	named entity 'infection' named entity 'infants' named entity 'median' named entity 'Ten' named entity 'A51' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software